Abstracts tagged "takayasu arteritis and tocilizumab"

Abstract Number: 2746 • 2018 ACR/ARHP Annual Meeting
Tocilizumab Monotherapy for Large Vessel Vasculitis: Results of 104-Week Treatment of a Prospective, Single-Center, Open Study
Shuntaro Saito, Ayumi Okuyama, Yusuke Okada, Akiko Shibata, Ryota Sakai, Kentaro Chino, Takahiko Kurasawa, Tsuneo Kondo, Hirofumi Takei and Koichi Amano, Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
Background/Purpose: To evaluate the efficacy and safety of tocilizumab (TCZ) monotherapy for Large Vessel Vasculitis (LVV), including Takayasu arteritis (TAK) and Giant cell arteritis (GCA).…
Abstract Number: 891 • 2017 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Tocilizumab in Patients with Refractory Takayasu Arteritis Treated Continuously over 52 Weeks: Results from Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial and Open-Label Extension in Japan
Yoshikazu Nakaoka¹, Mitsuaki Isobe², Syuji Takei³, Yoshiya Tanaka⁴, Tomonori Ishii⁵, Shumpei Yokota⁶, Akira Nomura⁷, Seitaro Yoshida⁷ and Norihiro Nishimoto⁸, ¹Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan, ²Sakakibara Heart Institute, Tokyo, Japan, ³Pediatrics of Developmental Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan, ⁶Laboratory of Pediatric Research, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan, ⁷Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, ⁸Department of Molecular Regulation for Intractable Disease, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan
Background/Purpose: Tocilizumab (TCZ), a humanized anti–IL-6 receptor antibody, showed a favorable trend toward relapse suppression in patients (pts) with refractory Takayasu arteritis (TAK) in a…
Abstract Number: 976 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Tocilizumab in Patients with Refractory Takayasu Arteritis: Results from a Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial in Japan
Yoshikazu Nakaoka¹, Mitsuaki Isobe², Syuji Takei³, Yoshiya Tanaka⁴, Tomonori Ishii⁵, Shumpei Yokota⁶, Akira Nomura⁷, Seitaro Yoshida⁷ and Norihiro Nishimoto⁸, ¹Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan, ²Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan, ³School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ⁴University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ⁶Laboratory of Pediatric Research, Medical Research Institute of Tokyo Medical School, Tokyo, Japan, ⁷Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, ⁸Osaka Rheumatology Clinic, Osaka, Japan
Background/Purpose: Glucocorticoids (GC) are the mainstay of treatment options for patients (pts) with Takayasu arteritis (TAK); however, long-term GC therapy is associated with adverse events…
Abstract Number: 3061 • 2015 ACR/ARHP Annual Meeting
Tocilizumab in Refractory Takayasu Arteritis. a Multicenter Study
Natalia Palmou¹, Montserrat Santos-Gómez^1,2, Javier Loricera¹, Ricardo Blanco¹, Jose L. Hernández³, Santos Castañeda⁴, Alicia Humbría⁵, Norberto Ortego-Centeno⁶, Beatriz Bravo⁷, Mercedes Freire^8,9, Sheila Melchor¹⁰, Mauricio Minguez¹¹, Juan Salvatierra¹², Carmen Gonzalez-Vela¹³, Vanesa Calvo-Río¹, Trinitario Pina¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ³Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ⁴Rheumatology, H.U. La Princesa, Madrid, Spain, ⁵Rheumatology, Hospital Universitario de La Princesa. IIS-Princesa, Madrid, Madrid, Spain, ⁶Systemic Autoimmune Diseases Unit, Hospital Universitario San Cecilio, Granada, Spain, ⁷Pediatric rheumatology, Hospital Virgen de las Nieves, Granada, Spain, ⁸Rheumatology, Hospital Universitario Juan Canalejo, La Coruña, Spain, ⁹Rheumatology, Complejo Hospitalario Universitario de A Coruña, La Coruna, Spain, ¹⁰Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ¹¹Department of Rheumatology, Hospital Universitario San Juan, Alicante, Spain, ¹²Rheumatology, University Hospital San Cecilio, Granada, Spain, ¹³Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: Takayasu arteritis (TA) is often refractory to corticosteroids and traditional immunosuppressive agents. Interleukin (IL)-6 plays an important role in the pathogenesis of TA. Tocilizumab…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].